SCHEMBL17328253

SCHEMBL17328253

CC(C)(C)OC(=O)N1CCC2(CC1)CN(C(=O)c1ccccn1)CC1(CC1)O2

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SCD5 Q86SK9 1/20 0.48
▸ L3MBTL1 Q9Y468 1/20 0.47
▸ GPR119 Q8TDV5 3/20 0.47
▸ POLB P06746 1/20 0.46
▸ EPHX2 P34913 1/20 0.46
▸ OPRD1 P41143 1/20 0.43
▸ OPRK1 P41145 1/20 0.43
▸ KDR P35968 1/20 0.42
▸ RBP4 P02753 2/20 0.42
▸ GRM5 P41594 1/20 0.41
▸ ALDH1A1 P00352 3/20 0.41
▸ CYP3A4 P08684 3/20 0.41
▸ CYP2D6 P10635 3/20 0.41
▸ HSD17B10 Q99714 3/20 0.41
▸ CKS1B P61024 1/20 0.41
▸ SKP1 P63208 1/20 0.41
▸ SKP2 Q13309 1/20 0.41
▸ CYP11B2 P19099 1/20 0.40
▸ CCR8 P51685 1/20 0.40
▸ KCNH2 Q12809 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17328261 0.88 EPHX2 (0.58) SCD5L3MBTL1GPR119POLBEPHX2
SCHEMBL17328260 0.85 GPR119 (0.45) SCD5L3MBTL1GPR119POLBEPHX2
SCHEMBL20058380 0.83 L3MBTL1 (0.55) L3MBTL1EPHX2RBP4ALDH1A1CYP3A4
SCHEMBL1088005 0.83 L3MBTL1 (0.69) L3MBTL1GPR119POLBKDRRBP4
SCHEMBL19107358 0.81 POLB (0.45) SCD5GPR119POLBALDH1A1CYP3A4
SCHEMBL18785466 0.80 MEN1 (0.49) SCD5GPR119HPGDTSHR
SCHEMBL17328258 0.80 PARP1 (0.47) SCD5GPR119POLBEPHX2TSHR
SCHEMBL19107369 0.80 POLB (0.49) SCD5POLBEPHX2ALDH1A1TSHR
SCHEMBL19120395 0.79 HTT (0.48) SCD5POLBALDH1A1HSD17B10TSHR
SCHEMBL17328248 0.78 EPHX2 (0.45) SCD5GPR119EPHX2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3149005-B1 AMIDE DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN ESTEVE LABOR DR (ES) 2018-04-18 — — EP disclosed
US-20170197984-A1 AMIDE DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN ESTEVE PHARMACEUTICALS, S.A. (ES) 2017-07-13 — — US disclosed
US-20170197984-A1 AMIDE DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN ESTEVE PHARMACEUTICALS, S.A. (ES) 2017-07-13 — — US disclosed
WO-2015185208-A1 AMIDE DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2015-12-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170197984-A1 AMIDE DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN OPRD1, SIGMAR1, OPRM1 SCD5 2111/4885L3MBTL1 2908/4885GPR119 328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback